RGEN - Repligen Corporation
61.10 -0.66 (-1.07%)
After hours: 4:11PM EDT
| Previous Close | 59.48 |
| Open | 59.20 |
| Bid | 49.07 x 900 |
| Ask | 69.00 x 1100 |
| Day's Range | 59.20 - 61.88 |
| 52 Week Range | 34.05 - 70.50 |
| Volume | 557,398 |
| Avg. Volume | 324,035 |
| Market Cap | 2.713B |
| Beta (3Y Monthly) | 0.90 |
| PE Ratio (TTM) | 166.92 |
| EPS (TTM) | 0.37 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.00 |
- Simply Wall St.•9 days ago
What Should Investors Know About Repligen Corporation’s (NASDAQ:RGEN) Future?
The most recent earnings update Repligen Corporation's (NASDAQ:RGEN) released in December 2018 indicated that the company experienced a substantial headwind with earnings declining by -41%. Below, I've laid out keyRead More...
- GuruFocus.com•20 days ago
Repligen Corp (RGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. Repligen Corp had annual average EBITDA growth of 1.80% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with RGEN.
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of RGEN earnings conference call or presentation 21-Feb-19 1:30pm GMT
Q4 2018 Repligen Corp Earnings Call
- Markit•24 days ago
See what the IHS Markit Score report has to say about Repligen Corp.
Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for RGEN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 21. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RGEN totaled $1.83 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Motley Fool•28 days agoRepligen Corp (RGEN) Q4 2018 Earnings Conference Call Transcript
RGEN earnings call for the period ending December 31, 2018.
- Zacks•28 days ago
Repligen (RGEN) Matches Q4 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 0.00% and 3.20%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•28 days ago
Repligen: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had net income of 12 cents per share. Earnings, adjusted for one-time gains and costs, came to 21 cents per share. The results matched Wall Street expectations. ...
- GlobeNewswire•28 days ago
Repligen Reports Fourth Quarter and Full Year 2018 Financial Results
Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growthOverall organic.
- GlobeNewswire•last month
Repligen to Report Fourth Quarter and Full Year 2018 Financial Results
WALTHAM, Mass., Feb. 15, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on.
- Simply Wall St.•2 months ago
Is Repligen Corporation’s (NASDAQ:RGEN) Liquidity Good Enough?
Mid-caps stocks, like Repligen Corporation (NASDAQ:RGEN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Incyte and Repligen
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
- Motley Fool•2 months ago
3 Pick-and-Shovel Biotechnology Stocks
These biotech suppliers have performed extremely well for investors. Here's why each of them is poised for prosperity.
- Motley Fool•2 months ago
How to Play It Safe in Biotech
Risk-averse investors might be surprised how safe some of these companies are in one of the most volatile sectors on the market.
- GlobeNewswire•2 months ago
Consolidated Research: 2019 Summary Expectations for Post, Westlake Chemical, Repligen, Weingarten Realty Investors, AptarGroup, and At Home Group — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- MoneyShow•2 months ago
Top Picks 2019- Repligen RGEN
Repligen (RGEN) is a pure-play supplier of bioprocessing technologies. It is a market leader in proteins (over 95% market share), where it has a near monopoly, explains Tyler Laundon, editor of Cabot Small-Cap Confidential.
- GlobeNewswire•3 months ago
Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2019 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will.
- Insider Monkey•3 months ago
Is Repligen Corporation (RGEN) A Good Stock To Buy?
Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- Simply Wall St.•3 months ago
Have Insiders Been Selling Repligen Corporation (NASDAQ:RGEN) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...
Zacks•3 months agoANIK vs. RGEN: Which Stock Should Value Investors Buy Now?
ANIK vs. RGEN: Which Stock Is the Better Value Option?
